This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Canopy Growth Corporation (CGC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Canopy Growth Corporation (CGC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buy Cronos (CRON) Stock Ahead of Earnings as Bet on Marijuana Comeback?
by Benjamin Rains
Should investors think about buying some shares of Cronos (CRON) ahead of earnings, as a bet on a marijuana market comeback?
4 Highly-Ranked Cheap Stocks Trading Under $10 to Buy Right Now
by Benjamin Rains
Today we highlighted 4 'cheap' stocks that are currently trading for under $10 per share that also sport a Zacks Rank #2 (Buy) or better that investors might want to consider buying right now...
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $19.86, marking a -1.44% move from the previous day.
5 Top-Ranked Cheap Stocks Trading Under $20 to Buy Right Now
by Benjamin Rains
Today we found 5 cheap stocks currently trading for under $20 per share using our Zacks Stock Screener that investors might want to buy heading into November...
Should You Buy the Dip in Marijuana ETFs Ahead of Earnings?
by Sanghamitra Saha
Hexo's downbeat results weigh on marijuana space but many key pot companies are likely to beat in November. This could provide a good entry points to pot ETFs.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $21.64 in the latest trading session, marking a -1.28% move from the prior day.
Canopy Growth Corporation (CGC) Stock Moves 0.69%: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $20.35, moving +0.69% from the previous trading session.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Implied Volatility Surging for Canopy Growth (CGC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Canopy Growth Corporation (CGC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $22.80, marking a +0.35% move from the previous day.
How to Invest in Emerging Industries Like Marijuana
by Tracey Ryniec
Investors are still crazy about the pot stocks despite this year's roller coaster ride.
Stocks Fall on U.S. Blacklist, China & the NBA and Buy Roku - Free Lunch
by Benjamin Rains
A look at the new U.S. blacklist on nearly 30 Chinese companies and how it might impact the upcoming trade talks. A dive into the dispute between the NBA and China, marijuana stocks, and why Roku is a Zacks Rank #1 (Strong Buy) - Free Lunch
Company News For Oct 4, 2019
by Zacks Equity Research
Companies in the news are: STZ, BBBY, PEP, CBIO
The Zacks Analyst Blog Highlights: Innovative Industrial, GW Pharmaceuticals and Canopy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Innovative Industrial, GW Pharmaceuticals and Canopy
Constellation Shares Tumble as Cannabis Investment Hinders Q2 Earnings
by Christopher Vargas
Constellation Brands (STZ) released Q2 earnings before the opening bell.
More U.S. Tariffs, October Economic Worries and a New Strong Buy Stock - Free Lunch
by Benjamin Rains
Another round of worrisome U.S. economic data, this time from the services sector. President Trump and the U.S. are set to roll out new tariffs on the EU. A look at PepsiCo (PEP) and others. And why Crocs is a Zacks Rank #1 (Strong Buy) stock.
Constellation Brands (STZ) Beats on Q2 Earnings, Updates View
by Zacks Equity Research
Constellation Brands (STZ) posts robust second-quarter fiscal 2020 results. Further, it revises earnings view for the fiscal year.
Alibaba, Bonanza Creek Energy, Constellation Brands and Canopy Growth highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Alibaba, Bonanza Creek Energy, Constellation Brands and Canopy Growth highlighted as Zacks Bull and Bear of the Day
Pot Stocks to Win as America Roots for Decriminalizing Drugs
by Tirthankar Chakraborty
Marijuana stocks have reversed recent losses as report finds that Americans favor decriminalizing all drugs. Thus, investing in cannabis stocks for the moment won't be a bad proposition.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $21.98, moving +0.69% from the previous trading session.
Can Constellation (STZ) Keep The Party Going: Earning BMO Thursday
by Daniel Laboe
Constellation Brands is outpacing the rest of the industry with its strategic positioning and operational excellence.
Can Beer Business Aid Constellation Brands' (STZ) Q2 Earnings?
by Zacks Equity Research
Momentum in the beer business positions Constellation Brands (STZ) for solid top and bottom-line growth in second-quarter fiscal 2020.
Is Constellation Brands (STZ) Stock a Buy Heading into Q2 Earnings?
by Benjamin Rains
Should investors consider buying shares of Constellation Brands (STZ) as we head into the release of its second quarter fiscal 2020 earnings results, due out on Thursday, October 3?
Epidolex Progresses: Will the Marijuana Drug Market Boom?
by Indrajit Bandyopadhyay
Cannabis (or marijuana) based medical products have the potential to become the next booming industry.